New indication

"Convince me..."

AREDIA
paromomycin disodium

For the treatment of osteolytic bone metastases and bone pain in breast cancer

The Facts

A single 90mg i.v. infusion every 4 weeks:

Cuts skeletal morbidity by a third or more 1,2

Reduces non-vertebral fracture rate by around a third 3,4

Reduces incidence of radiotherapy to bone by up to 45% 1,2

Delays mean time to skeletal complications 1,2

Relieves bone pain and reduces analgesic use 1,2

For the full evidence call 01403 323047

Presentation
Vials containing 90mg of sterile lyophilised paromomycin disodium. This dry powder, after reconstitution and appropriate dilution is for slow intravenous infusion. Indication
Osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer or multiple myeloma. Dosage
Following reconstitution of AREDIA dry powder (90mg in 10ml water), AREDIA should be given by slow intravenous infusion in 0.9% w/v sodium chloride intravenous infusion BP. Adults and elderly : 90mg by slow intravenous infusion in 0.9% w/v sodium chloride intravenous infusion BP every 4 weeks. In patients with breast cancer this may also be administered at 3 weekly intervals to coincide with chemotherapy if desired. Infusion rate should not exceed 90mg/90min., and concentrations should not exceed 90mg/125ml. No dose adjustment is necessary for patients with renal impairment, but infusion rate should not exceed 20mg/hour. Not recommended for children. See full prescribing information.

Contra-indications
Known hypersensitivity to paromomycin disodium or other biphosphonates. Precautions
Monitoring of calcium and phosphate. Do not administer as a bolus injection. Do not co-administer with other biphosphonates or calcium-containing infusion solutions.

Caution in patients with pre-existing renal disease or a predisposition to renal impairment. Caution in patients in whom an acute pyrexial reaction could be hazardous to Cardiac disease. Pregnancy AREDIA should not be administered during pregnancy except in cases of life-threatening hypercalcaemia. Side-effects
Fever and influenza-like symptoms, asymptomatic hypercalcaemia, hyperphosphataemia. Occasionally reactions at infusion site, transient bone pain, arthralgia, myalgia, generalized pain, nausea, vomiting, headache, lymphocytopenia and hypomagnesaemia. Rarely muscle cramps, anorexia, abdominal pain, diarrhoea, constipation, dyspepsia, symptoms and signs of hypercalcaemia, agitation, confusion, dizziness, insomnia, somnolence, lethargy, anaemia, leucopenia, hirsutism, hypercalcaemia, rash, pruritus, hypercalcaemic hypercalciuria, hypeparathyroidism. For further information see full prescribing information.

Legal category
POM. Packs containing one AREDIA 90mg vial (PL00001/0177) and one 10ml solvent ampoule of Water for Injections Ph.Eur. (PL00001/0169), basic NHS price £155.80. 5 denotes registered trademark. For prescribing information is available on request from Ciba Laboratories, Horsham, West Sussex RH12 4AB. Telephone (01403) 272827. Date of preparation June 1996.

References
3. Clinical Trial Protocol 18. Data on file, Ciba Laboratories, Wimblehurst Road, Horsham, West Sussex, RH12 4AB.

Please note: References 1 and 3 both relate to the same clinical trial. References 2 and 4 both relate to the same clinical trial.

© Ciba-Geigy PLC 1996
WITH CHEMO*

RELATED ANAEMIA

EVERYDAY TASKS CAN BE A REAL UPHILL STRUGGLE.

*Platinum based